These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 26813134)

  • 1. [Clinical significance of serum bone metabolic markers in diagnosis and monitoring of myeloma bone disease].
    Peng F; Fu R; Liu H; Wang Y; Ding K; Ding S; Liu Z; Ruan E; Qu W; Wang H; Xing L; Wang X; Wang G; Song J; Wu Y; Li L; Liu H; Guan J; Shao Z
    Zhonghua Yi Xue Za Zhi; 2015 Nov; 95(42):3436-9. PubMed ID: 26813134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical significance of osteoblast precursors and osteoclast precursors in earlier diagnosis and monitoring of myeloma bone disease.
    Fu R; Peng F; Liu H; Wang Y; Li L; Wang G; Song J; Shao Z
    Ann Hematol; 2016 Jun; 95(7):1099-106. PubMed ID: 27118542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical characteristics of bone disease in multiple myeloma and clinical significance of monitoring bone metabolic markers].
    Chu B; Lu MQ; Wu MQ; Shi L; Fu LN; Gao S; Fang LJ; Xiang QQ; Bao L
    Zhonghua Yi Xue Za Zhi; 2016 May; 96(18):1424-9. PubMed ID: 27266350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The influence and clinical significance of proteasome inhibitor on serum bone metabolite markers in patients with myeloma bone disease].
    Ma RJ; Yang SW; Yuan XL; Jiang L; Yang J; Wang Z; Zhang Y; Lei PC; Zhang L; Shang BJ; Cheng LN; Zhu ZM
    Zhonghua Yi Xue Za Zhi; 2020 Jul; 100(26):2032-2035. PubMed ID: 32654448
    [No Abstract]   [Full Text] [Related]  

  • 5. [Clinical significance of the ratio of serum beta-CTX/PINP in multiple myeloma bone diseases and bone metastases].
    Yang SW; Ma RJ; Zhao JJ; Yuan XL; Jiang L; Yang J; Lei PC; Zhang Y; Zhang L; Liu G; Wang F; Zhu ZM
    Zhonghua Yi Xue Za Zhi; 2018 Aug; 98(32):2583-2587. PubMed ID: 30220144
    [No Abstract]   [Full Text] [Related]  

  • 6. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
    Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A
    Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
    Ebert W; Muley T; Herb KP; Schmidt-Gayk H
    Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide.
    Tähtelä R; Seppänen J; Laitinen K; Katajamäki A; Risteli J; Välimäki MJ
    Osteoporos Int; 2005 Sep; 16(9):1109-16. PubMed ID: 15605190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TRACP 5b and CTX as osteological markers of delayed fracture healing.
    Moghaddam A; Müller U; Roth HJ; Wentzensen A; Grützner PA; Zimmermann G
    Injury; 2011 Aug; 42(8):758-64. PubMed ID: 21168135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover.
    Nenonen A; Cheng S; Ivaska KK; Alatalo SL; Lehtimäki T; Schmidt-Gayk H; Uusi-Rasi K; Heinonen A; Kannus P; Sievänen H; Vuori I; Väänänen HK; Halleen JM
    J Bone Miner Res; 2005 Oct; 20(10):1804-12. PubMed ID: 16355501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical utility of TRACP-5b to monitor anti-resorptive treatments of osteoporosis.
    Gossiel F; Ugur A; Peel NFA; Walsh JS; Eastell R
    Osteoporos Int; 2022 Jun; 33(6):1357-1363. PubMed ID: 35102444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Measurement and clinical significance of serum DKK-1 and sRANKL levels in multiple myeloma].
    Bao L; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2011 Mar; 50(3):243-7. PubMed ID: 21600091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relationship between Bone Markers and the Progression of Multiple Myeloma].
    Liu Y; Ke XY; Tian L; Wan W; Dong F; Wang J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1433-1436. PubMed ID: 27784370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carboxy-terminal telopeptide (CTX) and amino-terminal propeptide (PINP) of type I collagen as markers of bone metastases in patients with non-small cell lung cancer.
    Lumachi F; Santeufemia DA; Del Conte A; Mazza F; Tozzoli R; Chiara GB; Basso SM
    Anticancer Res; 2013 Jun; 33(6):2593-6. PubMed ID: 23749913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients.
    Tang C; Liu Y; Qin H; Li X; Guo W; Li J; Wang W; Qu L; Hu H; Xu C; Zheng L; Huang Y; Liu B; Gao H; Halleen JM; Liu X
    Clin Chim Acta; 2013 Nov; 426():102-7. PubMed ID: 24055775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
    Terpos E; Heath DJ; Rahemtulla A; Zervas K; Chantry A; Anagnostopoulos A; Pouli A; Katodritou E; Verrou E; Vervessou EC; Dimopoulos MA; Croucher PI
    Br J Haematol; 2006 Dec; 135(5):688-92. PubMed ID: 17107351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
    Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
    J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different patterns of change in bone turnover markers during treatment with bone-modifying agents for breast cancer patients with bone metastases.
    Nishimukai A; Higuchi T; Ozawa H; Yanai A; Miyagawa Y; Murase K; Imamura M; Takatsuka Y; Miyoshi Y
    Breast Cancer; 2017 Mar; 24(2):245-253. PubMed ID: 27040403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis.
    Guañabens N; Parés A; Alvarez L; Martínez de Osaba MJ; Monegal A; Peris P; Ballesta AM; Rodés J
    J Bone Miner Res; 1998 Apr; 13(4):731-8. PubMed ID: 9580479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
    Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.